



November 2, 2018

**BSE Limited**

Corporate Service Department  
1st Floor, New Trading Ring  
Rotunda Building, P.J. Tower  
Dalal Street, Fort  
**Mumbai - 400 001**

**The National Stock Exchange of India Ltd.**

Exchange Plaza, 5<sup>th</sup> Floor,  
Bandra Kurla Complex  
Bandra (E)  
**Mumbai – 400 051**

Scrip Code: 530019

Scrip Code: JUBILANT

**Sub: Credit Rating**

Dear Sirs,

We enclose a communication pertaining to upgrade in outlook of Credit Rating of Jubilant Pharma Limited.

This is for your kind information and records.

Thanking you,

Yours faithfully,  
For Jubilant Life Sciences Limited

Rajiv Shah  
Company Secretary

Encl.: as above

**A Jubilant Bhartia Company**

OUR VALUES



**Jubilant Life Sciences Limited**

1-A, Sector 16-A,  
Noida-201 301, UP, India  
Tel: +91 120 4361000  
Fax: +91 120 4234895-96  
www.jubl.com

Regd Office:  
Bhartiagram, Gajraula  
Distt. Amroha - 244 223,  
UP, India  
CIN : L24116UP1978PLC004624



**Jubilant Life Sciences Ltd.**  
1A, Sector 16A, Noida – 201301, India  
Tel.: +91 120 4361000  
[www.jubl.com](http://www.jubl.com)

**S&P upgrades Jubilant Pharma outlook to positive on strong operating performance;  
'BB-' rating affirmed**

***Noida (UP), India, Friday, Nov 2, 2018***

Jubilant Life Sciences Ltd (JLL), an integrated global Pharmaceuticals and Life Sciences Company, has announced that further to the exchange notification dated 29<sup>th</sup> September 2016 with reference to the issue of US\$300 mn rated unsecured high yield bonds by materially wholly owned subsidiary, Jubilant Pharma Ltd, Singapore, (JPL), Standard & Poor Global Ratings, Singapore (S&P) has upgraded JPL outlook to positive from stable due to strong operating performance and also affirmed its BB- long-term issuer credit rating on JPL and the unsecured high yield bonds.

**About Jubilant Life Sciences Limited**

Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Other businesses including Drug Discovery Solutions and India Branded Pharmaceuticals. The Pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectibles and Non-sterile products through 6 USFDA approved manufacturing facilities in the US, Canada and India and a network of over 50 radio-pharmacies in the US. The Life Science Ingredients segment, is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through 5 manufacturing facilities in India. The Drug Discovery Solutions business, provides proprietary in-house innovation & collaborative research and partnership for out-licensing through 2 world class research centers in India. Jubilant Life Sciences Limited has a team of around 7,600 multicultural people across the globe and is committed to deliver value to its customers across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: [www.jubl.com](http://www.jubl.com).

**For more information, please contact:**

***For Investors***

Ravi Agrawal / Vineet Mayer  
Jubilant Life Sciences Limited  
Ph: +91-120 436 1002 / 1021  
E-mail: [ravi.agrawal@jubl.com](mailto:ravi.agrawal@jubl.com)  
[Vineet.mayer@jubl.com](mailto:Vineet.mayer@jubl.com)

Siddharth Rangnekar / Karl Kolah  
Citigate Dewe Rogerson  
Ph: +91 22 6645 1209 / 1220  
E-mail: [siddharth@cdr-india.com](mailto:siddharth@cdr-india.com)  
[karl@cdr-india.com](mailto:karl@cdr-india.com)



*Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. For detailed disclaimer in case of Jubilant Pharma Limited, please visit <http://www.jubilantpharma.com/fullpage.aspx?mpgid=1147&pgid=1147>*